News & Events
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit awards to 20 new non-executive employees.
READ MOREUnderstanding the Role of IGF-1 in Managing Acromegaly
Dr. Alan KrasnerChief Endocrinologist If you are living with acromegaly, you’ve likely heard your healthcare provider talk about "IGF-1" during your appointments. But what exactly is IGF-1, and why is it so important to understanding and managing your condition? IGF-1, short for Insulin-like Growth Factor-1, is a hormone produced primarily by the liver in response to growth hormone (GH).
READ MOREAcromegaly Awareness Day: Our Support to the Community Today and Beyond
Dana Pizzuti, M. D. Chief Medical and Development Officer Each year on November 1, the acromegaly community comes together to observe Acromegaly Awareness Day—an important moment in time to raise awareness of this rare endocrine disease and provide support for all those impacted by it.
READ MORECelebrating Women’s Leadership: Crinetics’ Commitment to Scientific and Strategic Excellence
Jacqui KirbyChief Corporate Affairs Officer As I reflect on Women’s History Month, I find myself reflecting on the inspiring leaders who have shaped the pharmaceutical industry through their vision and determination. Many of these leaders are celebrated scientists, researchers and physicians working to improve patient lives. As the newly appointed chief corporate affairs officer at Crinetics Pharmaceuticals, I find myself equally inspired by the remarkable female leaders in corporate affairs who have transformed how organizations articulate their vision, engage stakeholders and ultimately influence business performance.
READ MORECrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
READ MORECrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly PatientsAdditional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO – May 15, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL. One presentation is a post-hoc analysis showing investigational candidate paltusotine provided rapid and durable treatment effects and was well tolerated in surgically naïve patients with acromegaly.
READ MORECrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
